Strategies for Overcoming Immune Evasion in Bladder Cancer

Tumors intricately shape a highly immunosuppressive microenvironment, hampering effective antitumor immune responses through diverse mechanisms. Consequently, achieving optimal efficacy in cancer immunotherapy necessitates the reorganization of the tumor microenvironment and restoration of immune re...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2024-03, Vol.25 (6), p.3105
Main Authors: Shin, Juhyun, Park, Jeong Won, Kim, Seon Young, Lee, Jun Ho, Choi, Wahn Soo, Kim, Hyuk Soon
Format: Article
Language:English
Subjects:
Antibodies
Antigens
B cells
BCG
BCG vaccines
Bladder cancer
Cancer therapies
Chemotherapy
Clinical trials
Dendritic cells
Development and progression
Diseases
FDA approval
Health aspects
Humans
immune checkpoint inhibitor
Immune Evasion
Immune response
Immune system
immunoregulatory cell
Immunotherapy
Ligands
Lymphocytes
Medical prognosis
Medical research
Metastasis
Monoclonal antibodies
Relapse
Review
Tuberculosis
Tumor Microenvironment
Tumors
Urinary Bladder Neoplasms - pathology
Urological surgery
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c503t-942727d08f821c714a9c5ad6b3b214e212916a09a90f0f918823444580d3e5fa3
container_end_page
container_issue 6
container_start_page 3105
container_title International journal of molecular sciences
container_volume 25
creator Shin, Juhyun
Park, Jeong Won
Kim, Seon Young
Lee, Jun Ho
Choi, Wahn Soo
Kim, Hyuk Soon
description Tumors intricately shape a highly immunosuppressive microenvironment, hampering effective antitumor immune responses through diverse mechanisms. Consequently, achieving optimal efficacy in cancer immunotherapy necessitates the reorganization of the tumor microenvironment and restoration of immune responses. Bladder cancer, ranking as the second most prevalent malignant tumor of the urinary tract, presents a formidable challenge. Immunotherapeutic interventions including intravesical BCG and immune checkpoint inhibitors such as atezolizumab, avelumab, and pembrolizumab have been implemented. However, a substantial unmet need persists as a majority of bladder cancer patients across all stages do not respond adequately to immunotherapy. Bladder cancer establishes a microenvironment that can actively hinder an efficient anti-tumor immune response. A deeper understanding of immune evasion mechanisms in bladder cancer will aid in suppressing recurrence and identifying viable therapeutic targets. This review seeks to elucidate mechanisms of immune evasion specific to bladder cancer and explore novel pathways and molecular targets that might circumvent resistance to immunotherapy.
doi_str_mv 10.3390/ijms25063105
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ad57935dc70342449a46382d7e3ce528</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A788248013</galeid><doaj_id>oai_doaj_org_article_ad57935dc70342449a46382d7e3ce528</doaj_id><sourcerecordid>A788248013</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-942727d08f821c714a9c5ad6b3b214e212916a09a90f0f918823444580d3e5fa3</originalsourceid><addsrcrecordid>eNptkktvEzEQgFcIRB9w44xW4sKhKeNXbHOpSlQgUqUegLPl2LPB0a5d7N1I_HscUkqCkGXZsr_5RjOapnlF4JIxDe_CZihUwJwREE-aU8IpnQHM5dOD-0lzVsoGgDIq9PPmhCnBKUh12rz_MmY74jpgabuU27stZpeGENftchimiO3N1paQYhti-6G33mNuFzY6zC-aZ53tC758OM-bbx9vvi4-z27vPi0X17czJ4CNM82ppNKD6hQlThJutRPWz1dsRQlHSqgmcwvaauig00QpyjjnQoFnKDrLzpvl3uuT3Zj7HAabf5pkg_n9kPLa2DwG16OxXkjNhHcSGKeca8vnTFEvkTkUVFXX1d51P60G9A5jLb8_kh7_xPDdrNPWENASCJPV8PbBkNOPCctohlAc9r2NmKZiGBAOoLTeJXvzD7pJU461V5UCVrcm9C-1trWCELtUE7ud1FzL2gyuat5KXf6HqsvjEFyK2IX6fhRwsQ9wOZWSsXsskoDZDY45HJyKvz5szCP8Z1LYL2Uhub8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3003300912</pqid></control><display><type>article</type><title>Strategies for Overcoming Immune Evasion in Bladder Cancer</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Shin, Juhyun ; Park, Jeong Won ; Kim, Seon Young ; Lee, Jun Ho ; Choi, Wahn Soo ; Kim, Hyuk Soon</creator><creatorcontrib>Shin, Juhyun ; Park, Jeong Won ; Kim, Seon Young ; Lee, Jun Ho ; Choi, Wahn Soo ; Kim, Hyuk Soon</creatorcontrib><description>Tumors intricately shape a highly immunosuppressive microenvironment, hampering effective antitumor immune responses through diverse mechanisms. Consequently, achieving optimal efficacy in cancer immunotherapy necessitates the reorganization of the tumor microenvironment and restoration of immune responses. Bladder cancer, ranking as the second most prevalent malignant tumor of the urinary tract, presents a formidable challenge. Immunotherapeutic interventions including intravesical BCG and immune checkpoint inhibitors such as atezolizumab, avelumab, and pembrolizumab have been implemented. However, a substantial unmet need persists as a majority of bladder cancer patients across all stages do not respond adequately to immunotherapy. Bladder cancer establishes a microenvironment that can actively hinder an efficient anti-tumor immune response. A deeper understanding of immune evasion mechanisms in bladder cancer will aid in suppressing recurrence and identifying viable therapeutic targets. This review seeks to elucidate mechanisms of immune evasion specific to bladder cancer and explore novel pathways and molecular targets that might circumvent resistance to immunotherapy.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms25063105</identifier><identifier>PMID: 38542078</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antibodies ; Antigens ; B cells ; BCG ; BCG vaccines ; Bladder cancer ; Cancer therapies ; Chemotherapy ; Clinical trials ; Dendritic cells ; Development and progression ; Diseases ; FDA approval ; Health aspects ; Humans ; immune checkpoint inhibitor ; Immune Evasion ; Immune response ; Immune system ; immunoregulatory cell ; Immunotherapy ; Ligands ; Lymphocytes ; Medical prognosis ; Medical research ; Metastasis ; Monoclonal antibodies ; Relapse ; Review ; Tuberculosis ; Tumor Microenvironment ; Tumors ; Urinary Bladder Neoplasms - pathology ; Urological surgery</subject><ispartof>International journal of molecular sciences, 2024-03, Vol.25 (6), p.3105</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c503t-942727d08f821c714a9c5ad6b3b214e212916a09a90f0f918823444580d3e5fa3</cites><orcidid>0000-0002-0566-0142</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3003300912/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3003300912?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38542078$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shin, Juhyun</creatorcontrib><creatorcontrib>Park, Jeong Won</creatorcontrib><creatorcontrib>Kim, Seon Young</creatorcontrib><creatorcontrib>Lee, Jun Ho</creatorcontrib><creatorcontrib>Choi, Wahn Soo</creatorcontrib><creatorcontrib>Kim, Hyuk Soon</creatorcontrib><title>Strategies for Overcoming Immune Evasion in Bladder Cancer</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Tumors intricately shape a highly immunosuppressive microenvironment, hampering effective antitumor immune responses through diverse mechanisms. Consequently, achieving optimal efficacy in cancer immunotherapy necessitates the reorganization of the tumor microenvironment and restoration of immune responses. Bladder cancer, ranking as the second most prevalent malignant tumor of the urinary tract, presents a formidable challenge. Immunotherapeutic interventions including intravesical BCG and immune checkpoint inhibitors such as atezolizumab, avelumab, and pembrolizumab have been implemented. However, a substantial unmet need persists as a majority of bladder cancer patients across all stages do not respond adequately to immunotherapy. Bladder cancer establishes a microenvironment that can actively hinder an efficient anti-tumor immune response. A deeper understanding of immune evasion mechanisms in bladder cancer will aid in suppressing recurrence and identifying viable therapeutic targets. This review seeks to elucidate mechanisms of immune evasion specific to bladder cancer and explore novel pathways and molecular targets that might circumvent resistance to immunotherapy.</description><subject>Antibodies</subject><subject>Antigens</subject><subject>B cells</subject><subject>BCG</subject><subject>BCG vaccines</subject><subject>Bladder cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Dendritic cells</subject><subject>Development and progression</subject><subject>Diseases</subject><subject>FDA approval</subject><subject>Health aspects</subject><subject>Humans</subject><subject>immune checkpoint inhibitor</subject><subject>Immune Evasion</subject><subject>Immune response</subject><subject>Immune system</subject><subject>immunoregulatory cell</subject><subject>Immunotherapy</subject><subject>Ligands</subject><subject>Lymphocytes</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Relapse</subject><subject>Review</subject><subject>Tuberculosis</subject><subject>Tumor Microenvironment</subject><subject>Tumors</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urological surgery</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkktvEzEQgFcIRB9w44xW4sKhKeNXbHOpSlQgUqUegLPl2LPB0a5d7N1I_HscUkqCkGXZsr_5RjOapnlF4JIxDe_CZihUwJwREE-aU8IpnQHM5dOD-0lzVsoGgDIq9PPmhCnBKUh12rz_MmY74jpgabuU27stZpeGENftchimiO3N1paQYhti-6G33mNuFzY6zC-aZ53tC758OM-bbx9vvi4-z27vPi0X17czJ4CNM82ppNKD6hQlThJutRPWz1dsRQlHSqgmcwvaauig00QpyjjnQoFnKDrLzpvl3uuT3Zj7HAabf5pkg_n9kPLa2DwG16OxXkjNhHcSGKeca8vnTFEvkTkUVFXX1d51P60G9A5jLb8_kh7_xPDdrNPWENASCJPV8PbBkNOPCctohlAc9r2NmKZiGBAOoLTeJXvzD7pJU461V5UCVrcm9C-1trWCELtUE7ud1FzL2gyuat5KXf6HqsvjEFyK2IX6fhRwsQ9wOZWSsXsskoDZDY45HJyKvz5szCP8Z1LYL2Uhub8</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Shin, Juhyun</creator><creator>Park, Jeong Won</creator><creator>Kim, Seon Young</creator><creator>Lee, Jun Ho</creator><creator>Choi, Wahn Soo</creator><creator>Kim, Hyuk Soon</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0566-0142</orcidid></search><sort><creationdate>20240301</creationdate><title>Strategies for Overcoming Immune Evasion in Bladder Cancer</title><author>Shin, Juhyun ; Park, Jeong Won ; Kim, Seon Young ; Lee, Jun Ho ; Choi, Wahn Soo ; Kim, Hyuk Soon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-942727d08f821c714a9c5ad6b3b214e212916a09a90f0f918823444580d3e5fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibodies</topic><topic>Antigens</topic><topic>B cells</topic><topic>BCG</topic><topic>BCG vaccines</topic><topic>Bladder cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Dendritic cells</topic><topic>Development and progression</topic><topic>Diseases</topic><topic>FDA approval</topic><topic>Health aspects</topic><topic>Humans</topic><topic>immune checkpoint inhibitor</topic><topic>Immune Evasion</topic><topic>Immune response</topic><topic>Immune system</topic><topic>immunoregulatory cell</topic><topic>Immunotherapy</topic><topic>Ligands</topic><topic>Lymphocytes</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Relapse</topic><topic>Review</topic><topic>Tuberculosis</topic><topic>Tumor Microenvironment</topic><topic>Tumors</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urological surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shin, Juhyun</creatorcontrib><creatorcontrib>Park, Jeong Won</creatorcontrib><creatorcontrib>Kim, Seon Young</creatorcontrib><creatorcontrib>Lee, Jun Ho</creatorcontrib><creatorcontrib>Choi, Wahn Soo</creatorcontrib><creatorcontrib>Kim, Hyuk Soon</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shin, Juhyun</au><au>Park, Jeong Won</au><au>Kim, Seon Young</au><au>Lee, Jun Ho</au><au>Choi, Wahn Soo</au><au>Kim, Hyuk Soon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Strategies for Overcoming Immune Evasion in Bladder Cancer</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>25</volume><issue>6</issue><spage>3105</spage><pages>3105-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Tumors intricately shape a highly immunosuppressive microenvironment, hampering effective antitumor immune responses through diverse mechanisms. Consequently, achieving optimal efficacy in cancer immunotherapy necessitates the reorganization of the tumor microenvironment and restoration of immune responses. Bladder cancer, ranking as the second most prevalent malignant tumor of the urinary tract, presents a formidable challenge. Immunotherapeutic interventions including intravesical BCG and immune checkpoint inhibitors such as atezolizumab, avelumab, and pembrolizumab have been implemented. However, a substantial unmet need persists as a majority of bladder cancer patients across all stages do not respond adequately to immunotherapy. Bladder cancer establishes a microenvironment that can actively hinder an efficient anti-tumor immune response. A deeper understanding of immune evasion mechanisms in bladder cancer will aid in suppressing recurrence and identifying viable therapeutic targets. This review seeks to elucidate mechanisms of immune evasion specific to bladder cancer and explore novel pathways and molecular targets that might circumvent resistance to immunotherapy.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38542078</pmid><doi>10.3390/ijms25063105</doi><orcidid>https://orcid.org/0000-0002-0566-0142</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2024-03, Vol.25 (6), p.3105
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_ad57935dc70342449a46382d7e3ce528
source Publicly Available Content Database; PubMed Central
subjects Antibodies
Antigens
B cells
BCG
BCG vaccines
Bladder cancer
Cancer therapies
Chemotherapy
Clinical trials
Dendritic cells
Development and progression
Diseases
FDA approval
Health aspects
Humans
immune checkpoint inhibitor
Immune Evasion
Immune response
Immune system
immunoregulatory cell
Immunotherapy
Ligands
Lymphocytes
Medical prognosis
Medical research
Metastasis
Monoclonal antibodies
Relapse
Review
Tuberculosis
Tumor Microenvironment
Tumors
Urinary Bladder Neoplasms - pathology
Urological surgery
title Strategies for Overcoming Immune Evasion in Bladder Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T06%3A31%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Strategies%20for%20Overcoming%20Immune%20Evasion%20in%20Bladder%20Cancer&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Shin,%20Juhyun&rft.date=2024-03-01&rft.volume=25&rft.issue=6&rft.spage=3105&rft.pages=3105-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms25063105&rft_dat=%3Cgale_doaj_%3EA788248013%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c503t-942727d08f821c714a9c5ad6b3b214e212916a09a90f0f918823444580d3e5fa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3003300912&rft_id=info:pmid/38542078&rft_galeid=A788248013&rfr_iscdi=true